Zynex, Inc. (NASDAQ:ZYXI)

Brian feroldi...a bit speculative.

Speculative Pick: 2% allocation limit would be wise.

Zynex makes FDA-approved therapy devices for pain relief and other therapeutic benefits. NexWave, their lead product, is very versatile, highly portable, and cost effective. Like most of their prescription products, they are covered by most insurance policies. In cases where insurance will not cover the cost of the unit, the CEO insists on offering the device at reduced cost directly to the patient.

The company has enjoyed a recent surge in revenue due to their newly expanded, and accelerating sales force. I personally see this as a positive - the more doctors and therapists learn about these devices, the more they buy. Revenue has grown an average of 32.5% over the past five years, 63.6% for the last twelve months. They've also bested the industry with a 79% gross profit margin over the past 12 months. With great products covered by insurance, FDA approval, reasonable prices, accelerating growth, and tiny debt (0.86% of total capital), I'm betting on this company for the long haul.